ByJohn A
7 GLP-1 Telehealth Options I’d Actually Pay For (Ranked After Digging Into the Details)
The GLP-1 shopping process got messier in 2026, not simpler. Warning letters, brand-name settlement pressure, and new oral-drug pricing all landed close together, which made pharmacy identity and real cash price matter more than polished signup pages.
So I went through the actual pricing, pharmacy sourcing, and compliance posture of the main players. Here is where I landed.
1. HealthRX
Compounded semaglutide starting at $99 a month and compounded tirzepatide from $149. Those are genuinely the lowest entry prices I found for a provider that also names its pharmacy out loud: Manifest Pharmacy in Greer, South Carolina, a 503A-licensed compounder operating under USP-797 standards with lot-level tracking from bench to doorstep. LegitScript certified (cert 50087439). Physician review comes back in roughly 24 hours, and overnight shipping covers all 50 states at no extra charge. The efficacy figures the brand references come from published trials, SURMOUNT-1 (tirzepatide, approximately 21% body weight over 72 weeks) and STEP 1 (semaglutide, approximately 15% over 68 weeks), not from internal claims.
Important: compounded medications are not FDA-approved, regardless of the underlying active ingredient.
Best for: Cash-pay shoppers who want the lowest credible price and a named, traceable pharmacy rather than a vague “licensed compounder.”
Honest con: No insurance path. If your plan covers branded GLP-1s, run those numbers first.
2. FormBlends
FormBlends sits in an interesting spot. It publishes actual purity testing data on its compounded GLP-1 products: HPLC purity percentages, mass spectrometry identity confirmation, endotoxin and sterility results, with specific numbers attached. Most telehealth brands say “third-party tested” and leave it there. FormBlends does not. The pharmacy is FDA-registered and 503A-compliant. Per-vial pricing runs higher than HealthRX, semaglutide around $299 and tirzepatide around $349, but the lab documentation is spelled out rather than implied. It also carries a broader catalog of peptides covering recovery, longevity, and cognitive categories under the same physician oversight model. Ships to 47 states, not all 50.
Again: compounded, not FDA-approved.
Best for: Patients who want to see the actual assay numbers before injecting anything, or who want GLP-1 treatment plus a broader peptide protocol from a single provider.
Honest con: Costs more than HealthRX. Three-state gap in coverage could matter depending on where you live.
3. Mochi Health
Mochi puts board-certified obesity medicine clinicians on your chart, not general practitioners filling a queue. Compounded semaglutide runs about $99 a month, tirzepatide around $199. The monitoring is heavier than most cash-pay platforms, which matters if you have comorbidities or have struggled with medication adjustments before. Not a set-it-and-forget-it service.
Best for: People who want actual obesity medicine specialists and are comfortable paying more for tirzepatide.
Honest con: Tirzepatide pricing is higher than both HealthRX and FormBlends.
4. Hims & Hers
Post-settlement reality: Hims & Hers no longer offers compounded semaglutide. It moved to branded medications. Injectable Wegovy runs around $299 a month through the platform, oral semaglutide around $249, Zepbound around $399. With insurance plus a manufacturer savings card, some patients land at $0 to $25 a month. That is genuinely excellent if it works out. The variable is whether your insurance cooperates.
Best for: Insured patients whose plan is likely to cover branded GLP-1s.
Honest con: Without insurance, these prices are among the higher ones on this list.
5. Ro Body
Ro charges roughly $39 for the first month, then $74 to $149 per month for the platform. Medications are billed separately. The standout operational feature is a dedicated prior-authorization team that will actually push paperwork with your insurer, which saves real time if branded meds are the goal. Takes insurance for branded prescriptions.
Best for: People who want insurance billing handled for them and are willing to pay for that service layer.
Honest con: Total monthly cost after adding medication can climb quickly if insurance does not come through.
6. PlushCare
Membership is $19.99 a month. Same-day appointments are available. PlushCare focuses on branded medications and insurance billing rather than compounded options. It is the closest thing on this list to a normal doctor visit that happens to be online.
Best for: Anyone who already has solid insurance coverage and just needs a telehealth physician to write the prescription quickly.
Honest con: No compounded pathway, so cash-pay patients face full branded-medication pricing.
7. Calibrate
Calibrate runs a roughly 12-month structured program. Program fees and medications are billed separately, so the total cost adds up. The coaching component is heavier than any other option here, with regular check-ins built into the model. This is for someone who wants behavioral change infrastructure around the medication, not just the prescription.
Best for: Long-term accountability-seekers who want coaching plus medication in one structured program.
Honest con: The combined cost of program fees plus meds makes this one of the more expensive paths, and the commitment is longer than most alternatives.
Quick-Reference Table
| Provider | Starting Price | Compounded? | All 50 States? | Insurance Path? |
| HealthRX | $99/mo (sema) | Yes | Yes | No |
| FormBlends | ~$299/vial (sema) | Yes | 47 states | No |
| Mochi Health | $99/mo (sema) | Yes | Yes | No |
| Hims & Hers | ~$249/mo (oral) | No | Yes | Yes |
| Ro Body | $39 first mo + meds | No | Yes | Yes |
| PlushCare | $19.99/mo + meds | No | Yes | Yes |
| Calibrate | Program fee + meds | No | Yes | Partial |
Prices current as of mid-2026 and subject to change. Compounded medications are not FDA-approved products.
Common Questions
Is compounded semaglutide from HealthRX or Mochi Health actually the same drug as Ozempic?
Not exactly. The active ingredient, semaglutide, is the same molecule, but compounded versions are mixed by a 503A pharmacy rather than manufactured by Novo Nordisk. They are not FDA-approved products and have not gone through the same large-scale clinical testing as branded Ozempic or Wegovy. That distinction matters when evaluating risk.
Why did Hims & Hers stop offering compounded semaglutide while HealthRX and Mochi still do?
Hims & Hers exited compounded semaglutide specifically because of its March 2026 settlement with Novo Nordisk. Smaller platforms like HealthRX and Mochi Health were not parties to that settlement. Whether compounded semaglutide remains legally available longer term depends on FDA shortage status and ongoing federal litigation, neither of which is resolved as of mid-2026.
If FormBlends publishes HPLC and mass spectrometry data, does that mean its products are safer than competitors?
Published lab data is meaningfully better than a vague “third-party tested” claim, but it is not a safety guarantee. It tells you the batch matched identity and purity specs at the time of testing. It does not replicate the FDA’s full manufacturing oversight. Treat the documentation as a useful signal, not a substitute for regulatory approval.
Which of these providers makes the most sense if my employer health plan covers Wegovy?
Hims & Hers, Ro Body, and PlushCare all have insurance billing infrastructure. Ro Body’s prior-authorization team is the most hands-on option if you expect pushback from your insurer. PlushCare at $19.99 a month is the lowest platform fee if your coverage is already solid and approval is likely to go smoothly.
Does Calibrate’s 12-month commitment lock you into paying even if you stop losing weight or change your mind?
Calibrate bills program fees and medications separately, and its terms have changed over time. Before signing up, confirm the cancellation policy directly with the company. The structured coaching model is genuinely useful for some patients, but the longer commitment and split billing make the total cost harder to predict than a simple monthly subscription.
Sources
- FDA warning letters to telehealth and compounding firms, January-February 2026 (FDA.gov press releases)
- SURMOUNT-1 trial (tirzepatide), published in *New England Journal of Medicine*, 2022
- STEP 1 trial (semaglutide), published in *New England Journal of Medicine*, 2021
- Novo Nordisk-Hims & Hers settlement reporting, March 2026 (Reuters, Fierce Healthcare)
- Lilly orforglipron pricing via LillyDirect, April 2026 (company announcement, Bloomberg)
- LegitScript certification database (LegitScript.com)
- Individual provider pricing pages verified independently, May-June 2026
